HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced a significant advancement in neurodegenerative disease research. Leveraging the well-established Cuprizone animal model, FibroBiologics has demonstrated that intravenous fibroblasts can facili ...

Humacyte (HUMA) Q4 2024 Earnings Call March 28, 2025 04:23 PM ET Company Participants Tom Johnson - Director - Corporate CommunicationsLaura Niklason - Founder, President, CEO & DirectorDale Sander - CFO, Chief Corporate Development Officer & TreasurerJoshua Jennings - Managing DirectorVernon Bernardino - Managing Director Conference Call Participants Ryan Zimmerman - Managing Director & Medical Technology AnalystNone - AnalystBruce Jackson - Senior Analyst Operator morning, ladies and gentlemen, and welcom ...

Core Insights - Vericel (NASDAQ: VCEL) operates in the regenerative medicine sector, which is currently undervalued by the market [1] - The company has achieved steady revenue growth through FDA-approved products such as MACI, Epicel, and NexoBrid, contrasting with larger biotech firms focused on blockbuster drug approvals [1] Company Overview - Vericel has established a niche in regenerative medicine, differentiating itself from larger biotech companies [1] - The company’s revenue-generating products are recognized for their FDA approval, contributing to consistent revenue growth [1] Market Position - The market tends to overlook Vericel in favor of larger biotech names, despite its strong performance and growth potential [1] - The focus on high-growth companies in sectors with potential for exponential expansion aligns with Vericel's business model [1]